Can AI predict heart trouble in IBD patients?
NCT ID NCT07663201
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, to better understand their risk of serious heart problems like stroke and heart attack. Researchers will collect information on therapy, disease activity, lifestyle, and samples like DNA and stool. Using artificial intelligence, they hope to find better ways to predict cardiovascular risk in this group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to predict and prevent heart problems in people with IBD.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may not apply to all IBD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Consecutive patients attending Gastroenterology and Cardiology Departments at IRCCS San Donato Policlinic
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Established diagnosis of ulcerative colitis and Crohn's disease Exclusion Criteria: Age \> 18 years Not compliant with study protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular risk are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple-Pronged attack on gut inflammation put to the test
- Two biologics go head to head in ulcerative colitis
- Lab-Grown gut patches made from Patients' own cells tested against Crohn's ulcers
- New drug ATTO-1091 put to the test for safety in ulcerative colitis
- Antiparasitic drug tested as new weapon against ulcerative colitis
- Could your Donor's gut bacteria decide whether a stool transplant works?